Article citationsMore>>

Coustan-Smith, E., Song, G., Clark, C., Key, L., Liu, P., Mehrpooya, M., Stow, P., Su, X., Shurtleff, S., Pui, C.H., Downing, J.R. and Campana, D. (2011) New Markers for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Blood, 117, 6267-6276.
https://doi.org/10.1182/blood-2010-12-324004

has been cited by the following article:

• TITLE: Predictive Value of miRNA-181a in Pediatric Acute Lymphoblastic Leukemia

  AUTHORS: Asmaa El Desoky, Hosny Badrawy, Dina Ismail Abd El Razik, Khaled F. Riad, Omina N. Abdelhamid, Eman Hassan

  KEYWORDS: miR-181a, Micro-RNA, ALL

  JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.11, November 18, 2020

  ABSTRACT: Background: Acute lymphoblastic leukemia (ALL), a common pediatric malignant neoplasia, showed high relapse rate after induction therapy. Some miRNAs have been shown to regulate normal hematopoiesis and their disruption could contribute to leukemogenesis: Recently, specific miRNA, including miR-181a, was shown to be involved in the pathogenesis of ALL, serving as a biomarker for diagnosis and relapse of ALL. Aim of the Study: To evaluate miR-181a expression level as a predictive marker for children with acute lymphoblastic leukemia. Patients and Methods: 40 pediatric ALL patients were included in this study. miR-181a expression was assessed at diagnosis before start of treatment. Samples were either peripheral blood or bone marrow aspirate sample. Patients were evaluated clinically and laboratory after the induction therapy. Results: The remission rate was significantly higher in patients with high miR-181a expression compared to those with low expression (p Conclusion: The expression level of miR-181a was significantly higher in remission group than in non-remission group was and predict good response to induction therapy.